Evidence map›Paper›PMID 40082786›Full record

ArticleBMC cancer2025

Integration of intratumoral and peritumoral CT radiomic features with machine learning algorithms for predicting induction therapy response in locally advanced non-small cell lung cancer.

FangHao Cai, Zhengjun Guo, GuoYu Wang, FuPing Luo, Yang Yang, Min Lv, JiMin He, ZhiGang Xiu, Dan Tang, XiaoHui Bao and 3 more

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Prediction of neoadjuvant chemotherapy efficacy in patients with HER2-low breast cancer based on ultrasound radiomics.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

FangHao Cai *Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, No. 288 Tianwen Road, Nan'an District, Chongqing, 400010, China.
Zhengjun Guo *Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, No. 288 Tianwen Road, Nan'an District, Chongqing, 400010, China. guozhengjun@hospital.cqmu.edu.cn.
GuoYu WangDepartment of Oncology and Hematology, The First People's Hospital of Longquanyi District, No. 669, Donglang Road, Chengdu, 610100, China.
FuPing LuoDepartment of Oncology and Hematology, The First People's Hospital of Longquanyi District, No. 669, Donglang Road, Chengdu, 610100, China.
Yang YangDepartment of Oncology and Hematology, The First People's Hospital of Longquanyi District, No. 669, Donglang Road, Chengdu, 610100, China.
Min LvDepartment of Oncology and Hematology, The First People's Hospital of Longquanyi District, No. 669, Donglang Road, Chengdu, 610100, China.
JiMin HeDepartment of Oncology and Hematology, The First People's Hospital of Longquanyi District, No. 669, Donglang Road, Chengdu, 610100, China.
ZhiGang XiuDepartment of Oncology and Hematology, The First People's Hospital of Longquanyi District, No. 669, Donglang Road, Chengdu, 610100, China.
Dan TangDepartment of Oncology and Hematology, The First People's Hospital of Longquanyi District, No. 669, Donglang Road, Chengdu, 610100, China.
XiaoHui BaoDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, No. 288 Tianwen Road, Nan'an District, Chongqing, 400010, China.
XiaoYue ZhangDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, No. 288 Tianwen Road, Nan'an District, Chongqing, 400010, China.
ZhenZhou YangDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, No. 288 Tianwen Road, Nan'an District, Chongqing, 400010, China. yangzz@cqmu.edu.cn.
Zhi ChenDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, No. 288 Tianwen Road, Nan'an District, Chongqing, 400010, China. 2023440076@stu.cqmu.edu.cn.

Funding

Chengdu Longquanyi district health committee medical topic Program of Chengdu WJKY2024010National Natural Science Foundation of China No.82273572Natural Science Foundation of Chongqing CSTB2023NSCQ-MSX0059
6 · The paper itself

Abstract

objectivesTo extract intratumoral, peritumoral, and integrated intratumoral-peritumoral CT radiomic features, develop multi-source radiomic models using various machine learning algorithms to identify the optimal model, and integrate clinical factors to establish a nomogram for predicting the therapeutic response to induction therapy(IT) in locally advanced non-small cell lung cancer.

methodsThis study included 209 patients with locally advanced non-small cell lung cancer (LA-NSCLC) who received IT as the training cohort, and an external validation cohort comprising 50 patients from another center. Radiomic features were extracted from intratumoral, peritumoral, and integrated intratumoral-peritumoral regions by manually delineating the gross tumor volume (GTV) and an additional 3 mm surrounding area. Three machine learning algorithms-Support Vector Machine (SVM), XGBoost, and Gradient Boosting-were employed to construct radiomic models for each region. Model performance was evaluated in the external validation cohort using metrics such as Area Under the Curve (AUC), confusion matrix, accuracy, precision, recall, and F1 score. Finally, a comprehensive nomogram integrating the optimal radiomic model with independent clinical predictors was developed.

resultsThrough a comparison of optimal machine learning algorithms, INTRAPERI, INTRA, and PERI achieved the best performance with Gradient Boosting, SVM, and XGBoost, respectively. Compared to the INTRA_SVM and PERI_XGBoost INTRA models, the fusion model that integrates INTRA and peritumoral regions within a 3 mm margin around the tumor (INTRAPERI_GradientBoosting) showed better predictive performance in the training set, with AUCs of 93.7%, 82.5%, and 89.4%, respectively. In the clinical model, the PS score was identified as an independent predictive factor. The nomogram combining clinical factors with the INTRAPERI_GradientBoosting score demonstrated clinical predictive value.

conclusionThe INTRAPERI_GradientBoosting model, which integrates intra-tumoral and peritumoral features, performs better than the INTRA intra-tumoral and PERI peritumoral radiomics models in predicting the efficacy of IT therapy in LA-NSCLC. Additionally, the nomogram based on INTRAPERI intra-tumoral and peritumoral features combined with independent clinical predictors has clinical predictive value.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMachine LearningTomography, X-Ray ComputedAdultAgedAlgorithmsFemaleHumansInduction ChemotherapyMaleMiddle AgedNomogramsRadiomicsRetrospective StudiesSupport Vector MachineCT imagingInduction therapyIntra-tumoral featuresLocally advancedMachine learningNomogramNon-small cell lung cancer (NSCLC)Peritumoral featuresPredictive modelRadiomics

Identifiers

PMID40082786
PMCPMC11907900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.